Thermo Fisher Scientific (TMO)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$516.48-0.22%
Close 2026-07-07 · 1-day change
Reading TMO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TMO free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading TMO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TMO free→QuarterlyIQ Insights · TMO
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $516.48. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $516 TMO trades at 22× p/e, below its 35× p/e peer median, but our blended $477 fair value sits below the price. It's a high-confidence read. Analysts target $490–$639. Note: our $477 fair value sits below the entire analyst range ($490–$639). Not investment advice.
$490.00 – $639.00 (median $555.00) · 8 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 28% over what the business is worth with no growth; closing that gap needs roughly 6.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $22.29/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $555.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $329.68 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $269.08 | — | — | Hist. CAGR | high |
| graham number | 12M | $269.37 | — | — | TTM | high |
| Mgmt guidance | 12M | $371.24 | 35.3 | 10.51 | Mgmt | high |
| Peer EV/EBITDA | 12M | $120.88 | 15.5 | 14.73 | TTM | high |
| Peer P/FCF | 12M | $570.47 | 31.5 | 18.09 | TTM | high |
| Peer P/E | 12M | $818.07 | 35.3 | 23.16 | TTM | high |
| Peer P/S | 12M | $441.49 | 3.6 | 121.17 | TTM | high |
| PEG | 12M | $1033.98 | 44.6 | 23.16 | TTM | high |
| residual income | 12M | $179.11 | — | — | TTM | high |
| Own P/E history | 12M | $513.26 | 22.2 | 23.16 | TTM | high |
| triangulated | 12M | $829.44 | 35.3 | 23.48 | Triangulated | high |
| Mgmt guidance | 3Y | $516.15 | 35.3 | 14.61 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $684.97 | 31.5 | 21.72 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $879.39 | 35.3 | 24.90 | Analyst | medium |
| Peer P/S | 3Y | $448.99 | 3.6 | 123.23 | guidance | medium |
| PEG | 3Y | $1111.47 | 44.6 | 24.90 | Analyst | medium |
| Own P/E history | 3Y | $551.73 | 22.2 | 24.90 | Analyst | medium |
| Mgmt guidance | 5Y | $642.96 | 35.3 | 18.20 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $773.80 | 31.5 | 24.54 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $784.35 | 35.3 | 22.21 | Analyst | high |
| Peer P/S | 5Y | $400.46 | 3.6 | 109.91 | guidance | high |
| PEG | 5Y | $991.36 | 44.6 | 22.21 | Analyst | high |
| Own P/E history | 5Y | $492.11 | 22.2 | 22.21 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.